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Background: Myopia is a public health problem worldwide and its incidence increases with age. The use of
acupuncture to treat myopia is a common practice in China, however, the use of acupuncture to treat myopia is
disputed in other parts of the world. This study aims to determine the safety of acupuncture to treat myopia and
its efficacy over six months.
Methods/Design: A randomized, parallel, single-center, assessor- and statistician-blinded, controlled clinical trial will
be performed. A total of 100 teenagers, between seven and 12 years of age, with mild-to-moderate myopia and
spherical lenses <−6.00 D and cylindrical lenses <−1.50 D will be selected from the Xinjiang Uygur Autonomous
Region Institute of Traditional Chinese Medicine, a grade III level A teaching hospital in Urumqi, Xinjiang, China
(Xinjiang Medical University Affiliated Hospital of Traditional Medicine). The subjects will be randomly assigned to
two different groups (control and acupuncture groups), each group containing 50 subjects. The subjects in both
groups wear single-vision corrective lenses. In the acupuncture group, acupuncture will be performed daily for nine
consecutive days on five points (bilateral Cuanzhu, Tongziliao, Sibai, Muchuang, and Hegu), followed by no treatment for
one day. Six cycles of treatment will be undertaken continuously for a total of 60 days. Following 60 days of treatment, a
follow-up period of six months will be included. The primary outcome will be diopter determination. The secondary
outcomes will include distance visual acuity, axial length, lens thickness, ciliary body thickness, and subjective symptoms
of the eyes and entire body. The main time points for the evaluation of clinical efficacy will be the first, third, and sixth
months after treatment.
Discussion: This study will provide clinical observations of various indices following the use of acupuncture to treat
adolescents with mild-to-moderate myopia, as well as information on the safety of acupuncture.
Trial registration: Chinese Clinical Trial Registry (identifier: ChiCTR-TRC-13003448; registration date: 7 August 2013).
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Myopia is becoming increasingly common and has be-
come a worldwide public health issue [1]. In the United
States and Europe, the incidence of myopia is 20% to 50%
[2]; in Asian countries, such as mainland China, Taiwan,
Hong Kong, and Singapore, the incidence of myopia is 60* Correspondence: cums6140@hotmail.com
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unless otherwise stated.to 80% [3-5]. Over the past 50 to 60 years, the incidence
of myopia in East and Southeast Asian countries has rap-
idly increased. Approximately 80 to 90% of urban adoles-
cents in these countries have myopia on graduating from
high school [1]. Myopia often occurs between six and
eight years of age, develops rapidly between 13 and
16 years of age, and stabilizes after 16 years of age [6].
Treatment of myopia in modern medicine is mainly opto-
metric, and includes the use of spectacles (single-vision
lenses (SVLs) and progressive addition lenses [7] and con-
tact lenses [8,9]. Refractive surgeries include laser-assistedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and posterior chamber phakic intraocular lenses [13].
However, while the most commonly used treatment
method (optometric) can increase the best corrected vis-
ual acuity, optometric methods are unable to improve the
uncorrected visual acuity. Surgery can help eliminate the
need for glasses, but may lead to complications, as indi-
cated by long-term follow-up studies [13,14]. There is also
an age limit for performing such surgery, and it is consid-
ered as the last treatment choice for teenagers.
Acupuncture is highly valued in traditional Chinese
medicine, and enjoys a favorable history of more than
2,500 years. Acupuncture has helped millions of patients
around the world, and has been shown to be effective in
clinical treatment. In 1980, the World Health Organization
recommended acupuncture as an effective alternative ther-
apy [15]. Previous studies have confirmed that acupunc-
ture, ear pins, or ear massage can help treat mild myopia
(<−3.0 D) [16]. There are published reports on the use of
acupuncture in the treatment of adolescent myopia, but
most studies use visual acuity as the primary outcome
measure. Indeed, visual acuity, as determined by eye exam-
ination, is easily influenced by many external factors.
Therefore, we have designed a randomized controlled trial
based on the physiology and pathology of myopia. In
addition to using distance visual acuity, diopter, and axial
length (AL) [17] as indices of clinical observation, indices
such as ciliary body thickness [18] and lens thickness [19]
will also be utilized to obtain more objective and quan-
titative results. This trial aims to confirm the effective-




This trial was designed and will be implemented in ac-
cordance with the relevant provision on the protection
of rights and interests of the subjects in the Declaration
of Helsinki version 08 and the ‘Biological Ethics Review
Method Involving Humans’ by the Ministry of Health of
the People's Republic of China (2007). The implementa-
tion of this project has been reviewed and approved by
the Ethics Review Committee of Xinjiang Medical
University Affiliated Hospital of Traditional Chinese
Medicine. The Certificate number of the ethics review is
2013 XE008-1. Written informed consent will be obtained
from the guardians of each of the participants.
Study design
This study will be a randomized, parallel, single-center,
assessor- and statistician-blinded, controlled trial. The
included subjects will be assigned to groups in a 1:1 ra-
tio. The subjects (n = 100) will be randomly assigned to
experimental (n = 50) and control groups (n = 50). Theexperiments began in January 2013 and will be com-
pleted in December 2014. The aim of this study is to ob-
jectively evaluate the clinical efficacy of acupuncture at
five acupuncture points (bilateral Cuanzhu, Tongziliao,
Sibai, Muchuang, and Hegu) in adolescent teenagers
with mild-to-moderate myopia (Table 1, Figure 1). This
report will be compiled according to the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) 2013 Statement ‘Defining Standard Protocol
Items for Clinical Trials’ [20].
Recruitment
This study will be conducted in the Department of
Ophthalmology, Xinjiang Uygur Autonomous Region
Institute of Traditional Chinese Medicine (Xinjiang Medical
University Affiliated Hospital of Traditional Chinese
Medicine, a grade III level A teaching hospital). Adolescents
with mild-to-moderate myopia will be recruited from
the 27th Elementary School near the Xinjiang Uygur
Autonomous Region Institute of Traditional Chinese
Medicine after an ophthalmologic examination. Inclu-
sion criteria will be as follows: the result of retinoscopy
is myopic refractive error; distance visual acuity can be
corrected to normal using negative spherical or cylin-
drical lenses; near visual acuity and other visual func-
tions must be normal; myopia diopter spherical lenses
must be between −0.5 D and −6.00 D, and cylindrical
lenses <1.5 D, as measured under cycloplegia; and ado-
lescents must be between seven and 12 years of age. Ex-
clusion criteria will be as follows: subjects with serious
systemic diseases, such as cerebrovascular, liver, kidney,
hematopoietic system, and psychiatric diseases; long-
term use of other related drugs or treatments, which
have not been terminated; diopter < −0.5 D, or com-
bined with pathologic myopia-related fundus changes
and/or significant visual function impairment; and the
affected eyes have other diseases which affect the deter-
mination of acupuncture efficacy.
Withdrawal conditions
The withdrawal conditions will be as follows: the subject
has an allergic or serious adverse reaction and, based on
the judgment of the physician, the trial should be termi-
nated; if deterioration occurs during the trial and, based
on the judgment of the physician, the trial should be ter-
minated; or the guardians of the subject change medi-
cine at their own will or use Chinese or Western drugs
prohibited by this trial. Subjects can terminate participa-
tion in the trial as follows: subjects who decide to ter-
minate participation in the trial for any reason; subjects
or their guardians who are not willing to, or cannot con-
tinue the clinical trial, and thereby terminate participa-
tion in the trial; and subjects, although not required to
terminate participation in the trial, no longer accept the
Table 1 Time of visit and data collection
Data obtained/recorded Baseline Treatment phase Visit 1 Visit 2 Visit 3
−7 days 1-2 months 3 months 5 months 8 months
Signed informed consent ×
Medical history ×
Met the diagnostic standard/exclusion criteria ×
General record ×
Diagnosis ×
Visual acuity × × × ×
Diopter × × × ×
Axial length × × × ×
Lens thickness × × × ×
Ciliary body thickness × × × ×
Skin damage × × × × ×
Eye symptoms and systemic symptoms × × × × ×
Randomization ×
Group therapy ×
Case report form × × × ×
Adverse event × × × ×
Close-out ×
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(CRFs) for the withdrawn cases will be preserved. The
results of the last trial will be considered to be the final
results. The data on the clinical efficacy and adverse re-
actions of acupuncture will be fully analyzed.
Standards of excluded and dropout cases
Standards of dropout cases
All participants have the right to terminate the clinical
trial at any time. Subjects who do not complete the clin-
ical trial will be considered dropout cases. The common
causes of dropouts are as follows: adverse events, lack of
efficacy, violation of the trial plan, lost to follow-up
(including the subjects or their guardians who decided
to terminate the treatment), and other reasons.
Dropout cases
For dropout cases, the researchers will specify the reason
for dropping out in the CRF. At the same time, the re-
searchers will contact the guardians and complete the
assessment items; the causes for dropping out will be
made clear and specified in the CRF. The observational
data on all dropout cases will be preserved for statistical
analysis at the end of the trial.
Excluded cases
If the cases included conform to one of the following,
they will be excluded: mistakenly included; and lack of
treatment. The reason for a case being excluded will be
specified. The CRF will be preserved for future reference.Statistical analysis of the efficacy data will not be carried
out, however, the subjects who receive at least one treat-
ment session will be included in the analysis of adverse
reactions.
Recruitment strategies
The subjects will be informed of the details regarding
the trial plan and those who voluntarily participate in
the trial will receive free ophthalmologic examinations.
Following optometric evaluation, these subjects will re-
ceive the highest discount (30% off ) on glasses. Subjects
in the experimental group will receive a 50% discount
on acupuncture treatment. All subjects who receive a
follow-up eye exam will not pay a fee and will be permit-
ted to be fast-tracked. The subjects who will be included
in the experimental group will receive treatment any
time between 10:00 and 19:00 (Beijing time). If adverse
events occur during treatment, the treatment will be im-
mediately terminated, and help will be obtained from
the emergency department. According to the specific
condition which occurs after treatment, a consultation
involving at least three experts will be carried out to de-
cide whether or not to continue the clinical trial. Subject
compliance will be determined based on whether or not
the subject receives due treatment. The researchers will
ensure that the subjects in the experimental group fully
understand the importance of regular acupuncture and
compliance. During the observation period, the use of
drugs or other therapies to treat mild-to-moderate my-
opia will be prohibited.
Figure 1 Flow of participants.
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Randomization
Randomized sequences will be generated by the Medical
Research Design and Data Processing Center of Xinjiang
Medical University Affiliated Hospital of Traditional
Chinese Medicine as the third party. SPSS 19.0 (SPSS Inc.,
Chicago, Illinois, United States) software (seed = 20,000)
will be used to generate serial numbers for the subjects;
100 random numbers and the allocation sequence table of
the randomized group will be preserved as blind codes.
Subjects will be assigned to the experimental (n = 50) and
control groups (n = 50) at a ratio of 1:1.Allocation concealment
Based on the randomized sequences, the third party will
place paper strips with black characters on a greybackground into non-transparent envelopes which are
sealed with adhesive.
Implementation
The randomized sequences will be generated by the
third party. The researchers consist of personnel from
the Department of Ophthalmology at the Xinjiang Uygur
Autonomous Region Institute of Traditional Chinese
Medicine. The subjects will be allocated into experimen-
tal and control groups by researchers according to the
randomized sequences generated. One copy of the blind
codes containing the random serial numbers will be pre-
served by the third party and research director. The
physician responsible for determining the primary and
secondary outcomes will be blind to the grouping of
subjects and will not participate in the acupuncture
treatment. All outcomes will be assessed and the results
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the allocations of the different treatments.Figure 3 Location of hand acupoint. Bilateral Hegu (LI4) is used
for adolescents in the acupuncture group.Intervention
Subjects in the acupuncture group will wear SVLs.
Acupuncture will be performed at five acupuncture
points (bilateral Cuanzhu (BL2), Tongziliao (GB1), Sibai
(ST2), Muchuang (GB16), and Hegu (LI4), see Figures 2
and 3). Alcohol (75%) will be used to routinely disinfect
the local skin at the acupuncture points and 0.25 mm ×
0.4 mm disposable sterile acupuncture needles (Suzhou
Acupuncture & Moxibustion Appliance Co., Ltd., Suzhou,
China) will be used at acupuncture points Sibai and Hegu
to a depth of 0.5 to 1.0 cm. After achieving de-qi (Subjects
have a feeling of soreness, fullness, aching, heaviness at
and around the acupoints), the needle will be held in pos-
ition for 20 minutes. Cuanzhu will be acupunctured to a
depth of 0.3 to 0.5 cm. Tongziliao and Muchuang will be
acupunctured to a depth of 0.1 to 0.3 cm. After achieving
de-qi, the needle will be held in position for 20 minutes.
Acupuncture will be carried out once a day between 10:00
and 19:00 (Beijing time). One cycle of treatment will last
for nine days, followed by one day of no treatment. Six cy-
cles of treatment will be undertaken continuously for a
total of 60 days. The acupuncturist in this study, a phys-
ician with 18 years of experience in clinical acupuncture,
will not participate in objective examinations, such as vis-
ual acuity. Subjects in the control group will wear SVLs
without any other treatment affecting visual acuity. Obser-
vations will be carried out for two consecutive months.Figure 2 Location of facial acupoints. Four points are used for
adolescents in the acupuncture group which includes bilateral
Cuanzhu (BL2), Tongziliao (GB1), Sibai (ST2), and Muchuang (GB16).Data collection
Baseline data will be collected before the first treatment.
The information collected will include gender, date of
birth, ethnicity, height, birth weight, current body weight,
premature or full-term baby, parental myopia, sibling my-
opia, time of reading at a close distance, time of daily out-
door activities, performance of daily eye exercises, room
lighting, and bad reading habits (reading while lying, walk-
ing, or riding on the bus).Primary outcome
The primary outcome in this trial will be diopter measure-
ment [21]. After mydriasis using cyclopentolate hydrochlor-
ide eye drops (15 ml; Alcon-Couvreur, Puurs, Belgium), a
comprehensive refractometer (AOS-1,500; Nidek, Aichi,
Japan) will be used to conduct objective optometry
(computer optometry and retinoscopy), then subjective
optometrics. Subjective optometrics will be divided
into the following two parts: optometrics will be con-
ducted on a single eye (the right eye followed by the
left eye), and a bilateral eye balance examination. Sub-
jective optometrics of a single eye will be divided into
the following three stages: the initial maximum plus
the maximum visual acuity (MPMVA) will be identi-
fied, Jackson cross cylindrical lenses will be used to deter-
mine the axial direction and degree of the cylindrical lens,
and the MPMVA will be repeated. The results will be
recorded after optometrics. When the pupils recover, a
re-examination will be carried out (three days after the
use of cyclopentolate hydrochloride eye drops). After
re-examination, the glasses will be tried again. The de-
gree of the glasses will be marked on the glass trial
frame, to be chosen by the subjects based on subjective
judgment. Finally, the diopter of the glasses and pre-
scription glasses will be determined. The optometrist
will not participate in other parts of the trial. The main
time points for evaluation of clinical efficacy will be
the first, third, and sixth months after two months of
treatment.
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The secondary outcomes in this study will include dis-
tance visual acuity [22], AL [17], lens thickness [18], and
ciliary body thickness [19]. These indices will be mea-
sured before treatment, and at the first, third, and sixth
months after two months of treatment. The objective ex-
aminations will be recorded in the CRFs. The main time
points of evaluation will be the sixth month after treat-
ment or when the trial is terminated.
Distance visual acuity will be measured using a stand-
ard logarithmic visual acuity test chart (TR-B; Tongrui
Medical Equipment Co., Ltd., Tianjin, China), under suf-
ficient lighting to measure the parameters of visual acu-
ity, with a 5-m distance to the visual acuity test chart.
All visual acuity examinations in this study will be carried
out by one nurse in a fixed place who will not participate in
acupuncture treatment or clinical examinations. The specific
details of the subjects will not be disclosed to the nurse.
In order to measure AL and lens thicknesses, the sub-
ject will be placed in the supine position. Oxybuprocaine
Hydrochloride Eye Drops (20 ml, Santen Pharmaceutical
Co. Ltd. Suzhou, China) will be applied to the eye to be
examined, and topical anesthesia will be applied. The
subjects will be asked to watch the red light at the top of
the probe with the eye to be examined. A disinfected
ultrasound probe will be placed on the surface of the
cornea. Sound waves will pass through the middle of the
corneal vertex, the center of the lens, and the vitreous
body, to reach the macular fovea. The sound beam will
be kept in a vertical orientation. The AL and lens thick-
nesses will be measured. Ten sets of values will be se-
lected, with a measurement error within 0.1 mm [22].
The lens thickness is the axial distance from the front sur-
face to the posterior surface of the lens [19,23]. An ophthal-
mic ultrasound instrument (CINESCAN; Quantal Medical,
Paris, France) will be used for these measurements in the
proposed study. Ten measurements of a particular index
will usually be made, and these 10 measurements will be re-
corded and the average value obtained. The AL and lens
thickness measurements will be carried out by one full-
time physician, on a fixed instrument, and at a fixed loca-
tion. The physician will not participate in visual acuity
examinations and acupuncture treatment, and the specific
details with respect to the grouping of subjects will not be
disclosed to the physician.
In order to measure ciliary body thickness, oxybupro-
caine hydrochloride eye drops will be applied to the eye
to be examined. After topical anesthesia is applied, a dis-
infected eye cup of appropriate size will be placed be-
neath the upper eyelid. At this time, the subjects will be
asked to move the eye downward to prevent scratching
the cornea. The lower eyelid will then be pulled. The eye
cup will be placed beneath the lower eyelid, so that it is
immobilized between the eyelids and the eyeball.Distilled water will be poured into the eye cup. The
contralateral eye will gaze at the red indicator light on
the nasal side. An ultrasound biomicroscope (MD-300 L;
Meda Co. Ltd., Tianjin, China) will be used. A 50 mhz
transducer with 4 to 5 mm tissue penetration depth will
be used to measure ciliary body thickness at the tem-
poral corneoscleral limbus of the eye to be examined.
The image will then be obtained. The built-in ruler will be
used to measure ciliary body thickness (vertical distance)
2 mm behind the scleral spur [24,25]. The position of the
bilateral temporal side (nine points in the right eye, three
points in the left eye) will be measured once manually and
the results will be recorded. The same instrument will be
used for all measurements. The measurement of ciliary
body thickness in this research will be completed by one
full-time physician, using a fixed instrument, in a fixed
place. The physician will not participate in visual acuity ex-
aminations or acupuncture treatment, and the specific de-
tails of the subjects will not be disclosed to the physician.
Data management
An electronic CRF will be designed on the Research
Manager (Clinical Trial Management Public Platform,
Chengdu, China) clinical trials public management plat-
form. A printed version will also be obtained. According
to data management provisions, the electronic data will
be saved for at least 30 years in the form of a CD.
The electronic CRF will be designed on the Research
Manager clinical trials public management platform.
The examination, input, and modification of case obser-
vation tables will be registered in a timely registered to
ensure that the case observation tables are returned in a
timely fashion and entered into the database. The ori-
ginal documents will be stored in the Department of
Ophthalmology. The data administrator will be in charge
of data entry. To guarantee the accuracy of the data, two
data administrators will enter and check the data inde-
pendently. In the case of questions arising from the
CRFs, the data administrator will complete a data recheck
query (DRQ) and issue an enquiry to the researchers
through the clinical supervisor. The researchers will an-
swer and return the DRQ as soon as possible. The data
administrators will then revise, confirm, and enter the data
according to the researcher’s reply and a DRQ will be is-
sued again if necessary. All scientific research documents
will be stored in special-purpose filing cabinets and locked
to guarantee the security of the files stored. Custody of the
files will be maintained through an on-the-spot inspection
method. Personnel will be specifically assigned to manage
the files. Various written materials will be saved according
to needs. The information will be stored in a safe and
orderly means to avoid water damage, staining, and
crimping. The files will be kept clean and in good con-
dition without damage. After the data is entered, lost or
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multiple records will be inspected. The data will be val-
idated by error analysis. Data management software will
be used to build the database. Personnel will be specific-
ally assigned to oversee the management of electronic data
and organize the clinical research team in terms of data
entry, verification, reporting, and answering questions.
Harms
In the proposed study, adverse events, included bleeding,
hematoma formation, fainting, severe pain, and local in-
fection, will be reported [26]. If adverse events occur
during the observation period, details of these adverse
effects will be recorded in the CRFs.
Sample size and statistical analysis
Sample size
Based on the myopia diopter described in the literature
[27], the sample size will be estimated using the formula
for superiority test sample size for two quantitative samples
[28]. The inspection significance level α = 0.05 (two-sided)
with a combined standard deviation (S) of 0.25, will be ob-
tained according to the literature, where u1-α, u1-β are
the bounds of the one-sided standard normal deviation,
u1–0.05 = 1.645, and u1-o.20 = 0.845. δu is the effective
boundary (δu >0), assuming δu = 0.2; θ is the estimate of
the overall mean difference value of the acupuncture
and control groups, and will be set at 3.0 according to
the literature [27]. By substitution into the above for-
mula with n = 79 and an expected dropout rate of 20%,
a total of 100 cases will be included. The sample ratio
between the groups will be 1:1.
Statistical analysis
All statistical analyses will be performed using SPSS 17.0
statistics software. For quantitative data, the distribution
pattern and homogeneity of variance will be examined.
If there is a symmetric distribution, the mean (M) ±
standard deviation will be used for statistical description,
otherwise the M interquartile range (IQR) will be used
to describe the trend of concentration and amount of
scatter. If this condition is met, the Student's t-test will
be used to compare the differences between the quanti-
tative indices between the groups, otherwise the Wil-
coxon rank-sum test will be used. For categorical data
(binary classification and multiple classification), the
composition ratio will be used for statistical description.
Based on the observation of a theoretical frequency dis-
tribution, the χ2 or Fisher's exact test will be used, de-
pending on the specific situation. The ranked data will
be analyzed using the Wilcoxon rank-sum test.
Primary and secondary outcomes will be analyzed by
the superiority test in accordance with the principle of
intention-to-treat, using Per Protocol Set (PPS) and FullAnalysis Set (FAS) datasets. The indices of safety evalu-
ation will be analyzed using the Save Set (SS) dataset.
The significance level in this study will be set at α = 0.05,
and the one-sided test will be used. The detailed statis-
tical analytical methods for primary and secondary out-
comes and baseline data are shown in Table 2 (variables,
measures, and methods of analysis).Monitoring
In the proposed study, a Data Monitoring Committee
(DMC) will be installed; the quality control office of the en-
tire project will be set up in DMC. A quality control team
will also be set up and a person-in-charge will be appointed
(members are the researchers, consisting of personnel from
the Ethics Committee, statistical analysis personnel, and
clinical professionals (five people in total)) to identify prob-
lems in the project implementation process in a timely
manner and to implement the corresponding countermea-
sures. The collected data will be examined, and the re-
searchers will be supervised to control bias.Protocol amendments and confidentiality
Notification of major modifications to the project (inclu-
sion criteria, outcomes, and analytical method) will be
provided to the Ethics Committee, subjects, register, and
publisher. The researchers promise to keep the informa-
tion and technology involved in the files confidential.
The personal information on the subjects will be strictly
confidential, and not disclosed under any circumstances.
Moreover, a confidentiality agreement will be signed.Declaration of interest
This research will be funded by the Youth Science and
Technology Talents Project of Xinjiang Uygur Autono-
mous Region Health Department. The Xinjiang Uygur
Autonomous Region Health Department and the re-
searchers who take part in the proposed study will not have
any conflicts of interests. The researchers will not have any
conflicts of interests with the subjects and their guardians.Ancillary and post-trial care
When emergencies or adverse reactions are observed, the
researchers will carry out the corresponding countermea-
sures according to the symptoms to ensure the safety of
the subjects. The results of the treatment administered
will be reviewed by the project director. The treatment
and the results of treatment will be recorded in detail in
the CRFs, which will later be signed. If adverse reactions
related to treatment occur and need treatment, the re-
search team will meet the costs of treatment according to
relevant regulations. Patients who experience adverse ef-
fects are given economic compensation.
Table 2 Variables, measures, and methods of analysis
Variable/outcome Hypothesis Outcome measure Methods of analysis
1) Primary Intervention improved outcome
from baseline to 7 days
Adherence% (>80%) [binary]
Diopter Diopter reduced or increased after
treatment
Diopter [continuous] t-test (rank-sum test) or
repeated measurement
2) Secondary Intervention improved outcome
from baseline to 7 days
Adherence% (>80%) [binary]
Visual acuity Visual acuity did not increase or
decrease after treatment
Visual acuity changes [continuous] t-test (rank-sum test) or
repeated measurement
Axial length Axial length was not increased Axial length changes [continuous] t-test (rank-sum test) or
repeated measurement
Lens thickness Lens thickness was not increased Lens thickness changes [continuous] t-test (rank-sum test) or
repeated measurement
Ciliary body thickness Ciliary body thickness was not increased Ciliary body thickness changes [continuous] t-test (rank-sum test) or
repeated measurement
Eye symptoms and systemic
symptoms
No adverse symptoms No adverse symptoms Chi-squared test or
Fisher’s exact test
Compliance Compliance Cure rate [binary] Chi-squared test or
Fisher’s exact test




Adverse event Improvement occurred Presence of drug-related adverse event [binary] Chi-squared test or
Fisher’s exact test
3) Baseline analyses: Adherence% (>80%) [continuous]
Age CRF [continuous] t-test (rank-sum test)
Weight and height CRF [continuous] t-test (rank-sum test)
Female versus male CRF [binary] Chi-squared test or
Fisher’s exact test
Race CRF [more categories] Chi-squared test or
rank-sum test
Birth weight CRF [continuous] t-test (rank-sum test)
Preterm children CRF [binary] Chi-squared test or
Fisher’s exact test
Parental myopia or not CRF [binary] Chi-squared test or
Fisher’s exact test
Sibling myopia or not CRF [binary] Chi-squared test or
Fisher’s exact test
Daily close reading time CRF [continuous] t-test (rank-sum test)
Outdoor time CRF [continuous] t-test (rank-sum test)
Eye exercises every day or not CRF [binary] Chi-squared test or
Fisher’s exact test
Daily sleep time CRF [continuous] t-test (rank-sum test)
Room light conditions CRF [binary] Chi-squared test or
Fisher’s exact test
Poor reading habits CRF [more categories] Chi-squared test or
rank-sum test
CRF, case report form ; rank-sum test, Wilcoxon rank-sum test; t-test, Student’s t-test.
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Traditional Chinese medicine theory states that the ‘me-
ridian is the channel through which qi and blood circu-
late. An acupoint is the site where the qi of the viscera is
transferred and concentrated’ [29,30]; the meridian isthe pathway for the body surface to connect and interact
with the internal organs; and the acupuncture point is a
specific point on the meridians, forming a special func-
tional relationship with the corresponding viscera and
the related surface structure through the meridians.
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treatment effect. Therefore, traditional Chinese medicine
purports that ‘the meridian circulation is closely related
to the amount of meridian qi concentrated’ [31]. Acu-
puncture treatment has a clinical effect, and acts on spe-
cific meridians and collaterals and specific acupuncture
points [31]. Some studies suggested that acupuncture at
visual-related acupoints could modulate optical physi-
ology [32]. Acupuncture points are specific, but in a
relative sense [30]. Therefore, in the proposed study the
local points (Cuanzhu, Tongziliao, Sibai, Muchuang, and
Hegu) will be acupunctured simultaneously, and the
clinical efficacy of acupuncture treatment in adolescent
mild-to-moderate myopia will be determined.
The advantages of the proposed study will be four-fold.
Firstly, Cuanzhu, Tongziliao, Sibai, Muchuang, and Hegu
will be acupunctured to study the specific efficacy and
safety of acupuncture in adolescent mild-to-moderate my-
opia. Secondly, the acupuncturist involved in the proposed
study will have more than 10 years of experience in clin-
ical acupuncture. The acupuncture procedure in all sub-
jects in the experimental group will be carried out by the
acupuncturist, which will ensure consistency of acupunc-
ture treatment. Thirdly, the subjects will mainly be chil-
dren from a primary school near the hospital, which will
help to ensure regular follow-up visits and examinations
of the subjects. Fourthly, previous clinical experience has
shown that acupuncture treatment of adolescent simple
myopia has almost no side effects.
The limitations of the proposed study are three-fold.
Firstly, due to a limited budget, the proposed study will
not be a multicenter trial, which will influence the exter-
nal validity of the conclusions. Secondly, common fake
acupuncture methods include neighboring sham acu-
puncture, non-specific site acupuncture, superficial acu-
puncture, minimal acupuncture, and a placebo needle;
all of these methods could be used as a control, but with
obvious deficiencies [33]. Therefore, in the proposed
study a sham acupuncture group will not be included.
Quantitative, objective indices, such as diopter, AL, lens
thickness, and ciliary body thickness will be selected as
the outcomes to evaluate the clinical efficacy at a re-
duced bias. Thirdly, in the proposed study, 100 cases will
be included and followed up on for six months. To pre-
vent bias caused by loss-to-follow-up, the following mea-
sures will be adopted: first, the subjects will be from an
elementary school near the hospital. Second, before the
subjects are entered into the proposed study, their
guardians will fully understood the specific requirements
of the follow-up schedule, as outlined in the informed
consent form. Once the subjects are included in the study,
communication with the guardians will be strengthened
by phone calls or email. The subjects will be informed of
the follow-up examination time and place in advance. Thesubjects will receive the follow-up examination immedi-
ately after arriving.
This will be a randomized, parallel controlled trial, and
it is anticipated that acupuncture treatment of adoles-
cent mild-to-moderate myopia will be shown to be safe
and effective. The proposed study will demonstrate the
specificity of the meridians and acupuncture points and
provide evidence-based medical evidence on the use of
acupuncture to treat myopia.
Trial status
The first participant was included on 27 November 2013
and to date, six participants have been recruited. The
study will be finished on 30 June 2015.
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